8-K: Citius Oncology Completes Business Combination with TenX Keane Acquisition, Begins Trading on Nasdaq

Citius Oncology, Inc. has finalized its business combination with TenX Keane Acquisition, marking its debut on the Nasdaq Capital Market under the ticker symbol CTOR.

Summary

• Citius Oncology, Inc., formerly TenX Keane Acquisition, completed its business combination on August 12, 2024.
• TenX changed its jurisdiction of incorporation from the Cayman Islands to Delaware and renamed itself Citius Oncology, Inc.
• Each share of TenX ordinary stock converted to one share of Citius Oncology common stock.
• Citius Pharma received 65,627,262 shares of Citius Oncology common stock.
• Maxim Group and Newbridge Securities received 1,872,738 and 50,000 shares respectively for financial advisory fees.
• All options to purchase shares of the former Citius Oncology (SpinCo) were converted into options to purchase shares of Citius Oncology, Inc.
• Citius Pharma controls approximately 92.6% of the outstanding shares of Citius Oncology, Inc.
• The company's common stock began trading on the Nasdaq Capital Market as CTOR on August 13, 2024.
• Former TenX public shareholders own approximately 1.3% of the outstanding shares.
• The Sponsor and related parties own approximately 3.1% of the outstanding shares.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the successful completion of the merger and the start of trading on Nasdaq. However, there are some concerns about the company's debt, control structure, and reliance on Citius Pharma.

Positives

• The business combination was successfully completed, allowing Citius Oncology to operate as a public company.
• The company has secured a significant investment from Citius Pharma, providing a strong financial base.
• The company's shares are now trading on the Nasdaq Capital Market, increasing visibility and potential for investment.
• The company has a clear ownership structure with Citius Pharma as the majority shareholder.

Negatives

• Citius Pharma's majority ownership means the company is a controlled company and may not comply with certain corporate governance standards.
• The company has a significant amount of debt to Citius Pharma, which is repayable upon a future financing.
• The company waived certain closing conditions, including the transfer of the LYMPHIR trademark, which will now occur within 60 days of closing.
• The company has a history of material weaknesses in internal controls over financial reporting.

Risks

• The company may not realize the anticipated benefits of the business combination.
• The company needs substantial additional funds to operate and grow.
• The company's historical financial data may not be representative of future results.
• The company faces risks related to the commercialization of LYMPHIR and other product candidates.
• The company is dependent on third-party suppliers.
• The company may not be able to meet Nasdaq's continued listing standards.
• The company's stock price may be volatile due to various factors.
• The company is subject to risks arising from changes in the competitive environment and government regulations.

Future Outlook

The company's future success depends on its ability to commercialize LYMPHIR and other product candidates, secure additional funding, and manage its business effectively. The company may utilize exemptions from certain corporate governance standards as long as it remains a controlled company.

Management Comments

• The company does not presently intend to rely on these exemptions, but the company may opt to utilize these exemptions in the future as long as it remains a controlled company.

Industry Context

This announcement reflects a trend of special purpose acquisition companies (SPACs) merging with private companies to go public. The focus on oncology therapeutics aligns with the growing demand for innovative cancer treatments.

Comparison to Industry Standards

• The business combination is similar to other SPAC mergers in the biotech sector, such as the merger of Immunovant and Health Sciences Acquisitions Corporation.
• The ownership structure, with Citius Pharma holding a majority stake, is common in biotech companies that have spun out from larger entities, similar to the structure of companies like Viela Bio after its spin-out from AstraZeneca.
• The company's reliance on a shared services agreement with Citius Pharma is a common practice for newly formed companies, similar to the shared services agreements between companies like Organogenesis and its parent company.
• The company's focus on LYMPHIR is similar to other biotech companies that are developing targeted therapies for specific cancers, such as ADC Therapeutics with its antibody-drug conjugates.

Management Changes

Corporate Governance

Related Party Transactions

• Citius Pharma received 65,627,262 shares of Citius Oncology common stock.
• Citius Pharma made a capital contribution of $10,000,000 to the company.
• Citius Oncology issued a promissory note to Citius Pharma for $3,800,111.
• Citius Oncology entered into an Amended and Restated Shared Services Agreement with Citius Pharma.

Stakeholder Impact

• Shareholders of TenX received shares of Citius Oncology common stock.
• Citius Pharma became the majority shareholder of Citius Oncology.
• Employees of Citius Pharma may be involved in providing services to Citius Oncology.
• Customers and suppliers of Citius Pharma may be impacted by the new structure.

Next Steps

• The company will transfer the LYMPHIR trademark within 60 days.
• The company will notify the FDA of the transfer of ownership rights within 60 days.
• The company will focus on the development and commercialization of its product candidates.
• The company will likely seek additional financing to fund its operations.

Key Dates

Keywords

business combination, merger, Citius Oncology, TenX Keane Acquisition, Nasdaq, LYMPHIR, biotechnology, pharmaceutical, capital raise, stock issuance